APTT
Liver0 parametersReport in 48HrsAt Home
No Fasting Required
Details
The APTT test measures the time it takes for blood to clot via the intrinsic and common coagulation pathways
₹295₹418
29% OFF
FREE:AI Insights
APTT (Activated Partial Thromboplastin Time) - Comprehensive Medical Test Guide
- Why is it done?
- Measures the intrinsic and common pathways of blood clotting cascade by evaluating clotting factor activity and function
- Evaluates time required for blood plasma to clot after specific activation reagents are added
- Screens for bleeding disorders and clotting factor deficiencies (Factors VIII, IX, XI, XII, and fibrinogen)
- Monitors anticoagulation therapy with heparin or warfarin
- Detects presence of inhibitors or anticoagulants (lupus anticoagulant, factor-specific inhibitors)
- Investigates unexplained bleeding or bruising
- Pre-operative assessment before surgery to evaluate bleeding risk
- Baseline testing before starting anticoagulant therapy or when transitioning between anticoagulants
- Normal Range
- Reference Range: 30-40 seconds (may vary by laboratory and reagent used)
- Unit of Measurement: Seconds (sec)
- Normal Result Meaning: Blood clotting time is within expected range, indicating adequate clotting factors and normal intrinsic/common pathway function
- Prolonged (Elevated) APTT: >40 seconds - Blood takes longer than normal to clot, may indicate clotting factor deficiency, inhibitor presence, or anticoagulant effect
- Shortened (Low) APTT: <30 seconds - Blood clots faster than normal, may indicate increased clotting risk, hypercoagulability, or testing artifact
- Critical Values: Results >60 seconds usually prompt immediate laboratory and physician notification due to significant bleeding risk
- Therapeutic Range (on Heparin Therapy): Typically 1.5-2.5 times the normal baseline or 45-70 seconds depending on clinical situation
- Interpretation
- Prolonged APTT Causes:
- Clotting factor deficiencies (Factors VIII, IX, XI, XII, fibrinogen, prothrombin)
- Heparin therapy (unfractionated or low-molecular-weight when on high doses)
- Warfarin therapy (affects vitamin K-dependent factors)
- Lupus anticoagulant (autoimmune inhibitor)
- Factor-specific inhibitors (hemophilia with inhibitors)
- Disseminated intravascular coagulation (DIC)
- Severe liver disease affecting clotting factor synthesis
- Vitamin K deficiency (affects factors II, VII, IX, X)
- Fibrinogen abnormalities or severe hypofibrinogenemia
- Specific inherited bleeding disorders (Hemophilia A and B, von Willebrand disease)
- Shortened APPT Causes:
- Hypercoagulable states or thrombophilia conditions
- Increased Factor VIII levels
- Laboratory artifact or blood sample hemolysis
- Early pregnancy or estrogen use
- Mixing Study Interpretation:
- If APPT corrects with mixing study (patient plasma mixed with normal plasma) - suggests factor deficiency
- If APPT remains prolonged after mixing - suggests presence of inhibitor or anticoagulant
- Factors Affecting Test Results:
- Improper blood collection (insufficient blood or excess anticoagulant in collection tube)
- Hemolysis, lipemia, or icterus in sample
- Temperature variation during sample handling
- Delayed sample processing or prolonged storage
- Different laboratory reagents and analyzers producing slightly different values
- Patient medications (aspirin, NSAIDs, antibiotics, steroids)
- Prolonged APTT Causes:
- Associated Organs
- Primary Organs/Systems:
- Hematologic system (blood and blood-forming organs)
- Liver (primary site of most clotting factor synthesis)
- Bone marrow (production of platelets and blood cells involved in clotting)
- Conditions Associated with Abnormal Results:
- Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency)
- Von Willebrand Disease
- Liver disease and cirrhosis (impaired clotting factor synthesis)
- Kidney disease (uremia affecting platelet function and Factor V)
- Systemic Lupus Erythematosus (SLE) and antiphospholipid syndrome
- Disseminated Intravascular Coagulation (DIC) from infections, malignancy, trauma
- Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS)
- Acute leukemia and other hematologic malignancies
- Vitamin K deficiency and malabsorption syndromes
- Complications Associated with Abnormal Results:
- Prolonged APPT complications: Spontaneous bleeding, hemorrhage (GI, intracranial, joint), excessive bleeding after surgery or trauma, internal bleeding
- Shortened APPT complications: Venous thromboembolism (DVT, PE), arterial thrombosis, stroke, myocardial infarction, recurrent pregnancy loss
- Primary Organs/Systems:
- Follow-up Tests
- If APPT is Prolonged:
- Mixing study (1:1 mix of patient and normal plasma) - differentiates factor deficiency from inhibitor
- Prothrombin time (PT) - evaluates extrinsic pathway
- Fibrinogen level - assesses fibrinogen adequacy
- Platelet count - evaluates thrombocytopenia
- Specific factor assays (Factor VIII, IX, XI, XII levels)
- Lupus anticoagulant testing - if inhibitor suspected
- Thrombin time (TT) - assesses fibrinogen function
- Bleeding time - evaluates platelet function (if prolonged)
- Von Willebrand factor antigen and activity testing
- If APPT is Shortened or Normal:
- Thrombophilia testing if hypercoagulability suspected (Factor V Leiden, prothrombin mutation, antithrombin III, protein C/S)
- Repeat APPT if artifact suspected
- For Therapeutic Monitoring:
- Repeat APPT 24-48 hours after heparin initiation or dose change
- Regular monitoring (every 24 hours for first few days, then daily or as needed) during heparin therapy
- Baseline APPT before starting warfarin, then INR monitoring during warfarin therapy (APPT not used for warfarin monitoring)
- APPT monitoring when switching from heparin to warfarin
- Related Coagulation Studies (Complementary Information):
- Complete blood count (CBC) - platelet and hemoglobin levels
- Liver function tests - assess hepatic synthetic function
- Kidney function tests - evaluate renal contribution to coagulopathy
- If APPT is Prolonged:
- Fasting Required?
- Fasting Requirement: No
- Food/Fluid Restrictions: No fasting required; patient may eat and drink normally before test
- Medications: Continue all anticoagulant medications (heparin, warfarin, DOACs) as prescribed unless specifically instructed otherwise by physician
- Medications to Disclose: Inform laboratory of aspirin, NSAIDs, antibiotics, steroids, or any recent medication changes
- Patient Preparation:
- No special preparation needed
- Wear comfortable, loose-fitting clothing to facilitate blood draw
- Inform phlebotomist of anxiety about needles or history of difficult blood draws
- Ensure adequate hydration before test (drink water)
- Report any recent bleeding episodes or bleeding tendency to healthcare provider before test
- Sample Collection Details:
- Blood collected by venipuncture into a 3.2% sodium citrate tube (light blue-topped tube)
- Tube must be filled to correct volume (typically 2.7 mL) to maintain proper blood-to-anticoagulant ratio
- Sample must be inverted 3-4 times immediately after collection to mix anticoagulant
- Sample must be kept at room temperature and processed within 1-2 hours of collection
- Do not refrigerate or freeze sample before analysis
How our test process works!
